Several local organizations have welcomed a new partner to Lancaster-based Smart Health Innovation Lab, or iLab, which aims to bring innovative health care technologies to market faster.
Israel-based Mor Research Applications is a subsidiary of the large health maintenance organization Clalit Health Service, which has 4.3 million members, 14 hospitals and about 2,000 clinics, according to a news release.
Existing iLab partners were Aspire Ventures and its affiliate Clio Health; Capital BlueCross; and Penn Medicine Lancaster General Health.
Mor CEO Pini Ben-Elazar said the partnership “not only helps us enter the U.S. market, but represents a joining of international forces to pursue solutions for the challenges conceived and developed by Clalit's professionals.”
Aspire managing partner Essam Abadir called Israel “the Start-up Nation” and said the U.S. market is being opened to its “transformational technological force.”
Mor’s commercialization portfolio has more than 100 different projects and companies at various stages of development, according to the news release.
In March iLab announced that OneOme would be the third company to go through its 12-week program, following Emovi and NeuroFlow.
The new strategic partnership agreement also brings Mor and Clalit into the Aspire Ventures Precision Medicine Fund.
That fund was launched last year by Aspire and Lancaster General, which said they each committed to combined cash and in-kind investment of $15 million, and were seeking to raise an additional $270 million.
Asked how much money Mor is investing and how much control it is getting in return, Aspire said via email that those details have not yet been announced. It also said it is not at liberty to share updates on the fund’s financial status due to disclosure agreements.